Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol. 2019 Oct; 15(29):3309-3326.
View in:
PubMed
subject areas
Aminopyridines
Aminopyridines
Animals
Animals
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Benzimidazoles
Benzimidazoles
Breast Neoplasms
Breast Neoplasms
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 6
Drug Evaluation
Drug Evaluation
Female
Female
Follow-Up Studies
Follow-Up Studies
Humans
Humans
Mice
Mice
Molecular Targeted Therapy
Molecular Targeted Therapy
Neoplasm Metastasis
Neoplasm Metastasis
Piperazines
Piperazines
Prognosis
Prognosis
Purines
Purines
Pyridines
Pyridines
Receptors, Estrogen
Receptors, Estrogen
Survival Rate
Survival Rate
Tumor Cells, Cultured
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Xenograft Model Antitumor Assays